ARCHIVES

NCCS Names 7 To Board; FDA Approves Warning Labels for Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 29 No. 03 | January 17, 2003

Download PDF Visit The Full Archive

Related Articles

NSABP Accrual To Resume Soon; Group ponders Elections, Move To Fox Chase

May 27, 1994

Senate Increases NIH Funding for 2013, Rejects President’s $200+ Million Increase for Program Evaluation Activities

June 22, 2012

Clinical Trials Approved By NCI Last Month

March 29, 2002

UCSF Receives $125 Million Gift for Cancer Hospital

March 27, 2009

NCAB Committee Agrees On Seven Characteristics For Comprehensive Centers, Asks For New Division

May 12, 1989

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004